SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA (SLL) explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA (SLL) trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests an experimental drug called epcoritamab (GEN3013) in people with several types of B-cell lymphoma that have relapsed (come back) or are refractory (did not respond to prior treatment). The main goals are to find the safest and most effective dose, monitor side ef…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
CLL breakthrough: could some patients finally stop daily pills?
Disease control OngoingThis study looks at whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have very low levels of cancer cells (called MRD-negative) after taking venetoclax can stop the drug and stay healthy for at least a year. About 81 adults who are al…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:46 UTC